LifeMD, Inc. (NASDAQ:LFMD) Q1 2023 Earnings Call Transcript

LifeMD, Inc. (NASDAQ:LFMD) Q1 2023 Earnings Call Transcript March 22, 2023

Operator: Good afternoon. Thank you for joining us today to discuss the results for LifeMD’s Fourth Quarter and Full Year ended December 31, 2022. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer of LifeMD. . I’d like to remind everyone that today’s call is being hosted via webcast, and the recording will be made available via the link in today’s press release, which is available in the Investor Relations section of the company’s website. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements, which are subject to numerous risks and uncertainties that may cause the company’s actual results to differ materially from those projected.

These risks and uncertainties are described in the company’s 10-K and 10-Q filings and within other filings that LifeMD may make with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today, March 22, 2023. The company assumes no obligation to update or revise any forward-looking statements after today’s call, except as required by law. Also, please note that the management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD’s performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release issued earlier today.

Finally, I would like to remind everyone that today’s call is being recorded and will be available for replay in the Investor Relations section of the company’s website. Now I’d like to turn the call over to LifeMD’s CEO, Justin Schreiber. Please go ahead.

Justin Schreiber: Thank you, and good afternoon, everyone. Today, after the market closed, we issued a press release detailing our fourth quarter and full year results and uploaded an updated corporate presentation. The slides focused on our 2022 financial performance are also hyperlinked in our earnings release and on the Investor Relations page of our website. I’m pleased to announce that 2022 was a pivotal year for LifeMD, one in which we successfully pivoted from being a high-growth provider of telemedicine products into a diversified provider of differentiated telehealth services and products. I’d like to highlight several key initiatives we executed upon in 2022 that I believe best define our accomplishments and where LifeMD is heading.

I’ll start by saying, we’re pleased to report that LifeMD achieved consolidated adjusted EBITDA profitability in the fourth quarter of 2022, in line with the guidance we provided over the past year. This achievement represents a crucial inflection point for our company and is demonstrative of the quality of our products and services as well as our commitment to financial discipline. We are now well positioned to deliver strong double-digit top line growth with meaningful profitability in 2023 and beyond. While we temporarily experienced a slowdown in telehealth growth in the second half of 2022, consistent with our guidance, we have successfully realigned our marketing, product and technology investment to support ongoing growth in the most profitable areas of our company.

As reflected in the 2023 guidance we released earlier today, we expect this effort to produce top line growth of 20% to 25% in 2023 along with meaningful adjusted EBITDA profitability and the elimination of our cash burn by mid-2023. Second, last year, we launched our namesake brand, LifeMD which provides virtual primary care services. Our early results have been outstanding. Despite launching in mid-2022 with minimal early investment, we ended 2022 with approximately 7,000 VPC patients ahead of our previous guidance. We attribute this success to our proprietary telehealth platform and affiliated medical group, which I believe are our 2 most valuable assets. Our technology platform has robust capabilities that span virtual care, pharmacy and marketing, thanks to the integration of features like a clinician-centric electronic medical record system, proprietary algorithms for case load balancing and scheduling, CRM functionality, lab testing, digital prescription capabilities, patient provider, audio video interfacing, cloud pharmacy fulfillment and more.

Our platform allows us to provide nuanced treatment offerings and complex care journeys to deliver the highest level of care to our patients as is demonstrated by the consistently high reviews and feedback we received from our patients. The launch of our virtual primary care business has expanded our treatment options to cover hundreds of conditions, providing an invaluable gateway for us to engage with our patients and support their daily and long-term health care needs. Moving forward, we plan to continue to invest in and diversify treatment offerings on our virtual primary care platform and expends patient access by participating in Medicare and contracting with private payers. For 2023, we project the LifeMD’s primary care revenue or revenue from our virtual primary care business will exceed $5 million compared to just over $500,000 in 2022.

Third, in 2022, LifeMD launched its enterprise telehealth offerings, which support pharmaceutical, medical device and diagnostic companies seeking to enhance the commercialization of their products. According to IQVIA, the U.S. life sciences industry spends approximately $10 billion per year on digital solutions in this area. LifeMD offers an attractive, affordable and differentiated solution. By leveraging our proprietary technology platform, medical Group, established brands, pharmacy partnerships and patient support infrastructure, LifeMD offers a comprehensive and flexible infrastructure, making us an ideal telehealth partner for these companies. This infrastructure reaches a broader audience while helping with patient adherence and outcomes, all while enhancing the long-term revenue streams of our partners.

So far, during the past 2 quarters, new partnerships have formed and begun to grow, leaving us quite optimistic about future prospects for expanding these new offerings with existing and new partners in 2023 and beyond. We are also in active dialogue with a variety of other national organizations that are seeking to partner with a leading telehealth platform like LifeMD. We are excited about the immediate and long-term value creation and growth opportunity presented by these prospective partnerships. Fourth, we continue to scale our Work Simply subsidiary while enhancing and diversifying its workplace services platform. Under the leadership of its Co-Founder and CEO, Sean Fitzpatrick, WorkSimpli exceeded our expectations and generated approximately $36 million in revenue and $5 million in EBITDA in 2022.

We anticipate that these numbers will increase significantly in 2023 with projected revenue of $50 million to $55 million and EBITDA of $15 million to $20 million, with the potential for continued growth. In 2022, WorkSimpli made several important strides towards diversifying its business from a single product PDF platform into a multifaceted workplace and document services platform. Offering PDF, resume, proprietary forms and digital signature solutions. Looking ahead to 2023, the business plans to further differentiate and expand its consumer and small business offerings. Despite receiving numerous offers to buy the business, LifeMD voluntarily decided to retain its majority ownership position in WorkSimpli. We believe that WorkSimpli is at an important inflection point and that this decision will be materially accretive to future shareholder value.

Finally, during the latter half of 2022, LifeMD executed several important initiatives to further strengthen the company’s long-term liquidity and capital position. These initiatives include significantly reducing our cash burn and successfully closing a credit facility with Avenue Capital that provided us with an additional capacity up to $40 million. LifeMD is on a pathway to eliminate its cash burn by the middle of 2023. And I believe our actions have positioned the company for long-term success and enabled us to invest in the continued profitable growth of our business. With that, I will now turn the call over to our CFO, Marc Benathen, who will provide a summary of the financial results. Marc?

Marc Benathen: Thank you, Justin, and good afternoon, everyone. Consistent with our guidance for the past year, LifeMD delivered adjusted EBITDA profitability of $631,000 in the fourth quarter of 2022 marking the first quarterly adjusted EBITDA profit for LifeMD. This was a particularly remarkable achievement in the evolution of our company when you consider that in the same year ago period, our adjusted EBITDA loss was a loss of $8.2 million. Additionally, as was released in full year 2023 guidance earlier today, we expect revenue growth of approximately 20% to 25% with adjusted EBITDA growing to between $12 million and $18 million for the year. We believe this reflects the remarkable financial progress we have made and we’ll continue to make — when you consider we had adjusted EBITDA losses of $15 million and $38 million in 2022 and 2021, respectively.

At the same time, we recently executed upon a significant debt financing with Avenue Capital to provide what we believe to be more than ample long-term capital to LifeMD and significantly bolster our current balance sheet. As we illustrated in our updated corporate presentation made available earlier today on ir.lifemd.com. We believe this enhanced liquidity, coupled with a minimal near-term cash burn, which we expect to be eliminated by mid-’23, puts LifeMD in a very strong financial position to execute our long-term growth plans while also allowing us to voluntarily retain the WorkSimpli asset, which we believe will continue to be accretive to future shareholder value. Now turning to results for the fourth quarter of ’22. Revenue in the fourth quarter totaled $28.1 million, up 3% as compared to the same year ago quarter.

Fourth quarter revenue was impacted by the noncash impact of $2.9 million related to the deferral of telehealth order shipments. 94% of total revenues in the fourth quarter were generated by recurring subscriptions. Telehealth net revenues declined by 20% to $16.4 million. However, excluding the impact of deferred order shipment revenue recognition net revenues declined by 6%, mostly reflecting the company’s refocus on advertising investment, targeting our most profitable segments with growth returning in 2023 off a more meaningful profitable base. WorkSimpli continued to execute extremely strongly against the plan we put in place early last year and delivered net revenues of $11.7 million, an increase of 71% versus prior year while generating an EBITDA margin exceeding 15% for the quarter.

On the telehealth side of the business, we increased our active subscriber base by 22% versus prior year. to end the quarter with over 169,000 active subscribers and saw our blended CACs declined by 18% versus the same year ago period. WorkSimpli subscriber count increased by 64% versus prior year to $168,000. Gross margins for the fourth quarter reached 86%, up 600 basis points versus prior year. Gross profit for the quarter totaled $24.1 million, an increase of 10% from the same year ago period. Operating expenses for the fourth quarter totaled $34.4 million a decrease of $1.1 million versus the year ago period. Operating expenses included $6.7 million of noncash expenses associated with stock-based compensation, intangible write-downs, depreciation and amortization expenses.

The intangible write-down was related to LifeMD truing up the valuation of the cleared acquisition assets which were originally valued assuming most earnouts were achieved in the time frame allotted. Importantly, the earnout liability has now been removed from the purchase consideration. In the fourth quarter of 2022, we also reduced our marketing expense as a percentage of revenue to 62% versus 77% of revenue in the same year ago period. Our GAAP net loss attributable to common stockholders for the fourth quarter totaled $12.7 million or $0.40 per share. This compares to a net loss attributable to the common stockholders of $19 million or $0.62 per share in the fourth quarter of 2021. Adjusted EPS, a non-GAAP financial measure that excludes noncash expenses, preferred stock dividends, litigation expense and foreign currency translation totaled a gain of $0.02 per share as compared to a loss of $0.27 per share in the same year ago period.

Adjusted EBITDA, a non-GAAP financial measure, excluding the same account categories as noted in adjusted EPS totaled a gain of $631,000 in the fourth quarter of 2022. This compares to an adjusted EBITDA loss of $8.2 million in the same year ago quarter. Now turning to results for the full year 2022. Revenue for the full year 2022 totaled $119 million, up 28% as compared to 2021. Telehealth net revenues grew by 21% to $82.6 million WorkSimpli net revenues grew 47% to $36.4 million. Gross margins for the full year reached 84%, up 300 basis points versus prior year. Gross profit for the year totaled $100.3 million, an increase of 34% from the prior year. Our GAAP net loss attributable to common stockholders for the full year totaled $46.8 million, or $1.57 per share.

This compares to a net loss attributable to common stockholders of $61.8 million or $2.29 per share in 2021. Adjusted EPS, a non-GAAP financial measure that excludes noncash expenses, preferred stock dividends, litigation expense and foreign currency translation totaled a loss of $0.47 per share as compared to a loss of $1.42 per share in the same year ago period. Adjusted EBITDA, a non-GAAP financial measure, excluding the same account categories as noted in adjusted EPS, totaled a loss of $14.7 million in 2022. This compares to an adjusted EBITDA loss of $38.3 million in 2021. Now turning to our balance sheet. Cash totaled $4 million as of December 31, 2022. Subsequent to quarter end, we closed on credit facilities from Avenue Capital providing up to $40 million of total capital with $15 million funded at closing.

As provided in our release earlier today, we have continued to reduce our cash burn and expect to eliminate it by the middle of 2023. This wraps up our financial results. I’d now like to turn the call back over to Justin.

Justin Schreiber: Thanks, Marc. In summary, 2022 was a pivotal year for LifeMD as we evolved from a singular-focused growth company in the telemedicine space to a diversified provider of telehealth services. We’re proud to have demonstrated our ability to build LifeMD profitably with long-term sustainable growth, achieving adjusted EBITDA profitability in the fourth quarter of 2020. Looking ahead, we expect our profitability to continue to increase materially in 2023 and beyond with a rapid resumption of strong double-digit growth. We’re also excited about the growth of our virtual primary care platform, our enterprise business and the new treatment areas we’ve expanded into in 2022, such as insomnia and weight management. The product that we built at LifeMD is amazing.

If you are listening to this call or reading the transcript and you aren’t yet convinced of this, go to lifemd.com and schedule a virtual visit with one of our providers. It will be a great experience. We also recently posted videos on the medical team page of our website with many of the full-time providers in our affiliated medical group. Spending a few minutes watching some of these videos will give you a pretty good idea of the quality of doctors and nurse practitioners that practice on our platform. I assure you, you’ll be impressed. The opportunity for our brand is enormous. We are still in the early days of virtual care. I believe that over the next 5 to 10 years, technology-driven virtual and in-home health care will fundamentally change how most Americans interact with their providers and manage their health.

It is an enormous market opportunity, and LifeMD is positioned to be a long-term leader in this space. What’s even better than the market opportunity is the positive impact our company’s success and the success of our shareholders will have on millions of people’s lives. If you are invested in LifeMD, you are invested in helping people across America reach incredible doctors that they desperately need and live longer, healthier and happier live because of this. Before I close out, I want to take this opportunity to express my gratitude to all of our stakeholders. The Board of Directors of LifeMD and I appreciate your continued support of our company and our mission to improve access to incredible and affordable virtual health care. With that, we would like to open the call for Q&A.

See also 10 Cheap Semiconductor Stocks To Buy and 12 Best Performing Growth Stocks in 2022.

Q&A Session

Operator: . And our first question comes from the line of David Larsen with BTIG.

David Larsen: Congratulations on getting to profitability. That’s a great accomplishment. Can you maybe talk a little bit about the $28 million in revenue that was obviously a little bit lower than we were modeling. Even if you add back the $3 million it still came in, I think to almost flat sequentially. Just any more color there would be great.

Marc Benathen: Dave, this is Marc. A couple of things on that. One, as we’ve talked about in the last couple of calls, the fourth quarter is really where we finished out reallocating a lot of our spend in pruning certain areas that were not as profitable — And then number two, no secret to everyone we ran in Q4 prior to completing this financing with a fairly lean balance sheet. And I’d say overall, we’re slightly underinvested on marketing investment and in general, both to our subscribers as well as to new patients, which also had an impact on the quarterly revenue. Those are all things that are behind us now, and we’re tracking to obviously return back to double-digit growth rates starting in the first quarter.

David Larsen: So for the revenue guidance for 2023, what is the split between health care and software?

Marc Benathen: Yes. So health care is roughly around $100 million and the balance is roughly in the software arena. So we’re looking at the WorkSimpli business as being around the $45 million, $50 million mark and then the health care business being around $100 million to $105 million.

David Larsen: Okay. So a good sort of go-forward steady growth rate for the health care business would be 15% to 20%. Is that correct?

Marc Benathen: Yes, I’d say probably 20% plus. One of the things you have to remember is that some of the growth in the health care business is back loaded in the year as we continue to build the virtual primary care business. I think we’ve shown that we’ve been able to get a lot of scale in that business pretty quickly. We see a lot more opportunity in that business. But given the nature of that business as less revenue per month than, say, some of the higher average order value businesses like the product business, but with very high retention, it takes a little bit more time for those initial dollars to produce the same amount of revenue. So I think long-term growth rate telehealth is 20% plus because you’re going to start to see more traction coming from primary care and some of these newer offerings to take a little bit of time to build up.

David Larsen: Okay. And then at 4Q ’23, what sort of EBITDA margin would you expect on the software business and then also on the health care business?

Marc Benathen: I think it’s a little bit early for us to give that. I mean, we have it obviously embedded in the guidance, but both of the businesses will be profitable by — obviously, WorkSimpli is profitable right now. Both of them will be profitable by the middle of the year. I’m happy to provide that a little bit as we move throughout the year, but I think it’s a little bit premature to provide that.

David Larsen: Okay. And then for the $40 million credit facility, how much of that do you have access to right now? And is there any — are there any stipulations for example, you have to be at a certain EBITDA level in order to gain $20 million. Are there any contingencies or anything like that?